

Studienliste Onkologie RUCCC

Studie	Entität	Stadium	Linie	Titel	LKP	EudraCT-Number
aktiv						
FIRE 4.5	Kolorektal	metast.	first	Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer	Prof. Dr. Volker Heinemann , München	2015-004849-11
PANAMA	Kolorektal	metast.	first	Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer	PD Dr. med. Dominik Paul Modest, Berlin	2012-005422-30
ALPACA	Pankreas	metast.	first	Induction Treatment with nab-Paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and nab-Paclitaxel/Gemcitabine or Continuing Application of nab-Paclitaxel/Gemcitabine: A Randomized Phase II Study	Prof. Dr. Frank Kullmann, Klinikum Weiden	2014-004086-24
CONKO 007	Pankreas	lokal inop.	first	Randomisierte Phase-III-Studie zum Stellenwert einer Radiochemotherapie nach Induktionschemotherapie beim lokal begrenzten, inoperablen Pankreaskarzinom: Chemotherapie gefolgt von Radiochemotherapie im Vergleich zur alleinigen Chemotherapie	Prof. Dr. Rainer Fietkau Universitätsklinikum Erlangen	2009-014476-21
PREDICT	Pankreas	fortgeschritten	second	Second-line therapy with Nal-IRI after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer - predictive role of 1st-line therapy	Prof. Dr. med. Manfred P. Lutz, Saarbrücken	2016-005147-17

Studienliste Onkologie RUCC

Studie	Entität	Stadium	Linie	Titel	LKP	EudraCT-Number
aktiv						
IMPORTANCE	Kopf-Hals	metast.	second	Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma	Dr. Dorota Lubgan, Erlangen	2017-002122-20
MARGINALZONEN-LYMPHOM REGISTER	Marginalzonenlymphom			Nicht-interventionelles prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonen-Lymphomen	Dr. med. Peter Koch, Münster; Prof. Dr. C. Buske, Ulm	
PANTAX Ib	Pankreas	lokal inop, fortgeschr. oder metastasiert	first	An open-label phase Ib prospective clinical trial to investigate safety, tolerability and maximum tolerated dose for SCO-101 in combination with gemcitabine and nab-paclitaxel in inoperable pancreatic cancer patients.	Prof., DMSc, Morten Ladekarl, Aalborg, Dänemark	2020-002627-11
ELDERLY AIO KRK 0117	Kolorektal	lokal inop, fortgeschr. oder metastasiert	first	Aflibercept and 5-FU vs. FOLFOX as 1st line treatment option for elderly or frail elderly patients with metastatic colorectal cancer	Prof. Dr. med. Ralf-Dieter Hofheinz, Mannheim	2017-000329-11
MIRATI 849-010	Kolorektal	fortgeschritten	on or after first line	A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy	-	2020-004048-27
ACO/ARO/AIO 18.1	Rektum			Kurzzeit-Radiotherapie versus Radiochemotherapie, gefolgt von konsolidierter Chemo-therapie und selektivem Organerhalt für Patienten mit MRT-definierten intermediären und Hoch-Risiko-Rektumkarzinom.	Prof. Dr. Claus Rödel	

Studienliste Onkologie RUCCC

Studie	Entität	Stadium	Linie	Titel	LKP	EudraCT-Number
aktiv						
AIO 18.2	Rektum	fortgeschritten	first	Preoperative FOLFOX versus postoperative risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure	Prof. Dr. Ralf-Dieter Hofheinz, Heidelberg	2018-001356-35
ANTONIO AIO-KRK-0220	Kolorektal	operabel	first	Perioperative/Adjuvant atezolizumab with or without the immunomodulatory IMM-101 in patients with MSI-high or MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy	Prof. Dr. S. Kasper-Virchow, Essen	2020-002715-21
GOBLET	Pankreas/ Kolorektal	lokal inop, fortgeschr. oder metastasiert	first - third	A phase 1 / 2 multiple-indication biomarker, safety, and efficacy study in advanced or metastatic Gastrointestinal cancers exploring treatment combinations with pelaricic acid and atezolizumab	Prof. Dr. med. Dirk Arnold, Hamburg	2020-003996-16
BNT122-01	Kolorektal	operabel	first	A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection	Scott Kopetz MD, Houston Texas, US	2020-000451-12
ESPAC-6 AIO-PAK.0121	Pankreas	operabel	first	An open labelled phase III adjuvant trial of disease-free survival in patients with resected pancreatic ductal adenocarcinoma randomized to allocation of oxaliplatin- or gemcitabine-based chemotherapy by standard clinical criteria or by a transcriptomic treatment specific stratification signature	Prof. Dr. Dr. med. Markus W Buehler, Heidelberg	2020-004906-79
CIRCULATE AIO-KRK-0217	Kolorektal	operabel	first	Evaluierung der adjuvanten Therapie beim Dickdarmkrebs im Stadium II nach ctDNA-Bestimmung (CIRCULATE) AIO-KRK-0217	Prof. Dr. Gunnar Folprecht, Dresden	2018-003691-12
RACE	Gastroösophagealer Übergang	operabel	first	Neoadjuvant Radiochemotherapy versus Chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction (GEJ) RACE-trial: A randomized phase III joint study of the AIO, ARO and DGAV	Prof. Dr. med. Ralf-Dieter Hofheinz, Mannheim	2018-001728-20

Studienliste Onkologie RUCCC

Studie	Entität	Stadium	Linie	Titel	LKP	EudraCT-Number
aktiv						
BERING-CRC	Kolorektal	metast.	second	Encorafenib and cetuximab in patients with metastatic, BRAFV600E-mutated, colorectal carcinoma: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Germany and Austria	Prof. Dr. med. Sebastian Stintzing, Berlin (wissenschaftlicher Leiter)	2018-003691-12
COUP-1	MZL	operabel/ inoperabel	first/second	Copanlisib and Rituximab in Marginal Zone Lymphoma Patients	Prof. Dr. Christian Buske, Ulm	2017-003150-16
CP-MGAH22-06 Macro Genics	Magen + Gastroösophagealer Übergang	fortgeschritten, metastasiert (unbehandelt)	first	A Phase 2/3 Trial to Evaluate Margetuximab in Combination with INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients with Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer		2019-004699-21
LYNK-003 (MK-7339-003)	Kolorektal	inoperabel oder metastasiert	second	A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)	Prof. Reinacher-Schick, Bochum	2019-000698-22
COLO-PREDICT PLUS 2.0	Kolon	St. II + III		Prospektive Erfassung der Rolle vom MSI und KRAS für die Prognose beim Kolonkarzinom im Stadium II + III.	Prof. Dr. A. Tannapfel	
GMALL-Register und Biomaterialbank	ALL			Biomaterialsammlung und prospektive Datenerfassung zu Diagnostik, Behandlung und Krankheitsverlauf der ALL des Erwachsenen.	Dr. Nicola Gökbüget	

Studienliste Onkologie RUCCC

Studie	Entität	Stadium	Linie	Titel	LKP	EudraCT-Number
aktiv						
SPACE	ES-SCLC			Einarmige Phase II Studie bei Patienten mit fortgeschrittenem kleinzelligen Bronchialkarzinom (ES-SCLC) in reduziertem Allgemeinzustand, die für eine Therapie mit Atezolizumab-Carboplatin-Etoposid qualifizieren.		
IPSEN Napoli3	Pankreas			Open label, multizentrische Phase III Studie zu Irinotecan Liposome Injektion, Oxaliplatin, 5-FU/ Leukovorin vs. nabPaclitaxel plus Gemcitabine bei Patienten ohne vorangegangene Chemotherapie bei metastasiertem Adenokarzinom des Pankreas.		
PanDa-DETECT (Biobank)	Pankreas			Monozentrisches Register für Patienten mit malignen Bauchspeicheldrüsenerkrankungen.		